PAREXEL Experts to Discuss Key Drug Development Insights at DIA 2016
June 20 2016 - 9:00AM
Business Wire
PAREXEL International Corporation (NASDAQ: PRXL), a leading
global biopharmaceutical services provider, today announced that
several of its experts will discuss key issues facing the industry
at the 52nd Annual Drug Information Association (DIA) meeting, held
from June 26-30, 2016 in Philadelphia.
PAREXEL will hold in-booth presentations and technology
demonstrations at booth 825 in the exhibit hall. Company experts
will share several formal presentations during the DIA 2016
program, including:
Sunday, June 26
- 1:00 p.m.: (Track 8 – Regulatory
Affairs) “Japan Regulatory Environment: Overview of the
Organization, Processes, Systems, and Changes Affecting
Pharmaceutical Development,” Alberto Grignolo, Corporate Vice
President, Global Strategy and Services
Monday, June 27
- 10:45 a.m.: (Track 8 – Regulatory
Affairs) “Take Advantage of Global Expedited Pathways:
Breakthrough, Sakigake, PRIME!,” Alberto Grignolo, Corporate Vice
President, Global Strategy and Services
- 10:45 a.m.: (Track 2 –
Project/Portfolio Management and Strategic Planning) “Hope Is Not a
Strategy: Quantifying Knowledge for Better Decision Making in
Clinical Development,” Colleen Russell, Associate Director,
Biostatistics, and Sharon Murray, Associate Director,
Biostatistics
- 1:00 p.m.: (Track 20 – Innovation
Theaters) “Balancing Rapid Approval with Demonstration of Value,”
Alberto Grignolo, Corporate Vice President, Global Strategy and
Services, and Michelle Hoiseth, Vice President, Business
Management
Tuesday, June 28
- 9:00 a.m.: (Track 21 – Poster
Presentations – Professional Poster Session) “U.S. Outcomes-Based
Drug Pricing: A Fad or the Future?” Michelle Hoiseth, Vice
President, Business Management
- 10:10 a.m.: (Track 21 – Poster
Presentations – Professional Poster Session) “Bridging the Gap: The
Need for a Paradigm Shift in Clinical Trial Design to Ensure
Continued Patient Access to Medicines,” Richard Macaulay, Senior
Consultant
- 10:30 a.m.: (Track 7 –
Technology/Data/Records and Submissions) “Implementing a Successful
Metadata Repository: The Journey of a Thousand Milestones Begins
with a Single Step,” Isabelle de Zegher, Vice President, Integrated
Solutions
- 4:00 p.m.: (Track 15 – Statistics)
“Statistical Issues in the Evaluation of Biosimilars,” Marek
Ancukiewicz, Principal Biostatistician
To schedule a briefing with a PAREXEL subject matter expert at
DIA 2016, email events@parexel.com. For more information about
PAREXEL visit booth 825 during the meeting or www.PAREXEL.com.
Information about the DIA 2016 can be found at
http://www.diahome.org.
About PAREXEL InternationalPAREXEL International
Corporation is a leading global biopharmaceutical services company,
providing a broad range of expertise-based clinical research,
consulting, medical communications, and technology solutions and
services to the worldwide pharmaceutical, biotechnology and medical
device industries. Committed to providing solutions that expedite
time-to-market and peak-market penetration, PAREXEL has developed
significant expertise across the development and commercialization
continuum, from drug development and regulatory consulting to
clinical pharmacology, clinical trials management, and
reimbursement. PAREXEL Informatics provides advanced technology
solutions, including medical imaging, to facilitate the clinical
development process. Headquartered near Boston, Massachusetts,
PAREXEL has offices in 82 locations in 51 countries around the
world, and had approximately 18,450 employees in the third quarter.
For more information about PAREXEL International, visit
www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered
trademarks of PAREXEL International Corporation or its affiliates.
All other trademarks are the property of their respective
owners.
This release contains “forward-looking” statements regarding
future results and events. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the foregoing,
the words “believes,” “anticipates,” “plans,” “expects,” “intends,”
“appears,” “estimates,” “projects,” “will,” “would,” “could,”
“should,” “targets,” and similar expressions are also intended to
identify forward-looking statements. The forward-looking statements
in this release involve a number of risks and uncertainties. Such
factors and others are discussed in the section entitled “Risk
Factors” of the Company’s most recent Annual Report on Form 10-K
and subsequent quarterly reports on Form 10-Q filed with the
Securities and Exchange Commission, which “Risk Factors” discussion
is incorporated by reference in this press release. The Company
specifically disclaims any obligation to update these
forward-looking statements in the future. These forward-looking
statements should not be relied upon as representing the Company’s
estimates or views as of any date subsequent to the date of this
press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160620005087/en/
PAREXEL InternationalCristi Barnett, +1
781-434-4019Cristi.Barnett@PAREXEL.comorPAN CommunicationsJenny
Gardynski, +1 617-502-4300PAREXEL@pancomm.com
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Apr 2023 to Apr 2024